| Literature DB >> 20066173 |
Bettina Wedi1, Ulrike Raap, Dorothea Wieczorek, Alexander Kapp.
Abstract
Urticaria is a group of diseases that share a distinct skin reaction pattern. Triggering of urticaria by infections has been discussed for many years but the exact role and pathogenesis of mast cell activation by infectious processes is unclear. In spontaneous acute urticaria there is no doubt for a causal relationship to infections and all chronic urticaria must have started as acute. Whereas in physical or distinct urticaria subtypes the evidence for infections is sparse, remission of annoying spontaneous chronic urticaria has been reported after successful treatment of persistent infections. Current summarizing available studies that evaluated the course of the chronic urticaria after proven Helicobacter eradication demonstrate a statistically significant benefit compared to untreated patients or Helicobacter-negative controls without urticaria (p < 0.001). Since infections can be easily treated some diagnostic procedures should be included in the routine work-up, especially the search for Helicobacter pylori. This review will update the reader regarding the role of infections in different urticaria subtypes.Entities:
Year: 2009 PMID: 20066173 PMCID: PMC2804274 DOI: 10.1186/1710-1492-5-10
Source DB: PubMed Journal: Allergy Asthma Clin Immunol ISSN: 1710-1484 Impact factor: 3.406
Number of reported infections in different urticaria subtypes published in PubMed (01.02.2009)
| Pathogen | acute UR | chronic | cold | DPU | AE | AAE | HAE |
|---|---|---|---|---|---|---|---|
| H. pylori | nd | +++ | 1 | nd | + | + | ++ |
| Streptococcus spp. | +++ | +++ | nd | nd | + | nd | Nd |
| Staphylococcus spp. | ++ | ++ | nd | nd | nd | nd | Nd |
| Yersinia ent. (persist.) | nd | +++ | nd | nd | nd | nd | Nd |
| Mycoplasma pneum. | + (c) | nd | + | nd | nd | nd | Nd |
| Trichinella | nd | 1 | nd | nd | nd | nd | Nd |
| Plasmodium falcip. | + | nd | nd | nd | nd | nd | Nd |
| HIV | nd | nd | + | nd | nd | nd | Nd |
| Influenza | + | nd | nd | nd | nd | nd | Nd |
| Adenovirus | + (c) | nd | nd | nd | nd | nd | Nd |
| Enterovirus | + (c) | nd | nd | nd | nd | nd | Nd |
| Rotavirus | + (c) | nd | nd | nd | nd | nd | Nd |
| RSV | + (c) | nd | nd | nd | nd | nd | Nd |
| Hepatitis A virus | + | nd | nd | nd | nd | nd | Nd |
| Hepatitis B virus | + | nd | + | nd | + | nd | Nd |
| Hepatitis C virus | nd | ++ | 1 | nd | nd | nd | Nd |
| Cytomegalovirus | + | + | + | nd | nd | nd | Nd |
| Epstein-Barr virus | + | + | nd | nd | + | nd | + |
| Parvovirus B19 | + | nd | nd | nd | + | nd | Nd |
| Norovirus | 1 | 1 | nd | nd | nd | nd | Nd |
| Blastocystis hominis | + | ++ | nd | 1 | 1 | nd | Nd |
| Giardia lamblia | nd | + | nd | nd | 1 | nd | Nd |
| Toxocara canis | nd | + | 1 | nd | nd | nd | Nd |
| Trichomonas vagin. | nd | 1 | nd | nd | nd | nd | Nd |
| Anisakis simplex | ++ | nd | nd | nd | nd | nd | Nd |
| Strongyloides sterc. | nd | + | nd | nd | + | nd | Nd |
| rhinopharnygitis | +++ | nd | nd | nd | ++ | nd | Nd |
| tonsillitis | nd | ++ | nd | nd | + | nd | Nd |
| sinusitis | nd | ++ | nd | nd | + | nd | Nd |
| dental infection | + | ++ | nd | nd | + | nd | Nd |
| urinary tract infection | ++ | ++ | nd | nd | + | nd | Nd |
Number of publications:
1, if n = 1; +, if n = 2-10; ++, if n = 11-99; +++, if n ≥ 100; nd, not described
*Search strategy in PubMed: titles/abstract for the respective pathogen and "urticaria"
Items with "urticaria" in title/abstract: 8336
Abbreviations: UR, urticaria; DPU, delayed pressure urticaria; AE, angioedema; histam., histaminergic; AAE, acquired angioedema; HAE, hereditary angioedema; (c), children
Pro-Studies evaluating Helicobacter pylori (HP) and chronic urticaria (CU), (only studies that included proven eradicated patients)
| H. pylori proven eradication rate (%) | first treatment regimen (days) | evaluation period in months | Remission or improvement rate (%) | First author | |||
|---|---|---|---|---|---|---|---|
| eradicated HP+ CU | untreated HP+ CU | untreated | |||||
| 39/46 (85) | OAC (14) | 3 | 36/39 (92)* | 10/20 (50) | nd | Yadav | [ |
| 39/45 (87) | OAC (14) | 2 and 4 | nd** | nd** | 0/33 | Magen | [ |
| 62/68 (91) | OAC (7)$ | nd | 41/55 (75) | nd | nd | Vazquez | [ |
| 26/26 (100) | OAC (4)$ | >12 | 19/26 (73) | nd | nd | Shiotani | [ |
| 24/24 (100) | OAC (7)$ | 4 | 19/21 (91) | 10/20 (50) | 33/53 (62) | Wedi | [ |
| 21/21 (100) | BM, ABM or BMT | not specified | 20/21 (95) | nd | nd | Kolibasova | [ |
| 20/20 (100) | OAC (7) | not specified | 14/20 (70) | nd | nd | Gaig | [ |
| 17/19 (89) | LAC, LAM (7) | 2 | 17/17 (100), CR in 6/17 | 2/9 (22) | nd | Fukuda | [ |
| 17/17 (100) | ABM or OA (7) | not specified | 17/17 (100) | nd | nd | Kalas | [ |
| 16/18 (89) | LAC (7) | 1-4 | 16/16 (100) | nd | 0/19 (0) | Di Campli | [ |
| 15/15 (100) | LAC (7) | >6 | 9/15 (60) | nd | nd | Sakurane | [ |
| 14/17 (82) | OA, OC or OMT (7) | 1.5-2.5 | 14/17 (82) | nd | 0/8 (0) | Tebbe | [ |
| 12/12 (100) | OAM (7) | not specified | 10/12 (83) | nd | nd | Bonamigo | [ |
*signif. increase of CU2QoL (p = 0.001)
**signif. Urticaria activity score decrease in eradicated HP+CU but not in untreated HP+CU or untreated HP-CU
$treatment was repeated or a reserve schedule was used until eradication was achieved
§9 of 13 studies (69%) used a triple treatment of proton pump inhibitor (O or L) plus amoxicillin and clarithromycin;
&study by Magen could not be included because remission/improvement rates were not described
Abbreviations: O, omeprazole; A, amoxicillin; C, clarithromycin; B, bismuth; M, metronidazole; T, tetracycline; L, lansoprazole; HP, Helicobacter pylori; CU, chronic urticaria; nd, not done;
Contra-Studies evaluating Helicobacter pylori (HP) and chronic urticaria (CU) (only studies that included proven eradicated patients)
| H. pylori proven eradication rate (%) | first treatment regimen (days) | evaluation period in months | Chronic urticaria remission or improvement rate (%) | First author | |||
|---|---|---|---|---|---|---|---|
| treated | untreated HP+ CU | untreated | |||||
| 29/31 (94) | OMC (7) | 4-12 | 6/31 (19) | 3/34 (9) | nd | Valsecchi | [ |
| 25/29 (86) | OAC (7) | nd | 1/25 (4) | nd | nd | Erel | [ |
| 24/30 (80) | OA (7) | 6 | 8/30 (27) | nd | nd | Wustlich | [ |
| 17/23 (74) | OAC (7) | 4-6 | 5/17 (29) | nd | 3/8 (38) | Özkaya-Bayazit | [ |
| 12/13 (92) | AM (7) | 4 | 8/11 (73) | 9/13 (69) | nd | Schrutka-Koelbel | [ |
| 12/15 (80) | OAC (7) | >12 | 3/12 (25) | nd | nd | Daudén | [ |
| 30/35 (86)* | LMA or LMT (7) | 5 | 8/30 (27) | 5/18 (28) | nd | Hook-Nikanne | [ |
| 3/11 (27) | LA (7) | 3-6 | 1/3 (33) | 4/14 (29) | nd | Schnyder | [ |
| 12/14 (80) | OAC (7) | 6 | 3/12 (25) | nd | nd | Moreira | [ |
§ 4/9 (44) studies used a triple treatment of proton pump inhibitor (O or L) plus amoxicillin and clarithromycin
Abbreviations: O, omeprazole; A, amoxicillin; C, clarithromycin; B, bismuth; M, metronidazole; T, tetracycline; L, lansoprazole; HP, Helicobacter pylori; CU, chronic urticaria; nd, not done.
Combination of the chronic urticaria remission/improvement rates of all studies, namely pro (see Table 2) and contra (see Table 3) together (= this review 2009) and comparison to the systematic review of Federman [29]].
| Chronic urticaria remission or improvement rate (%) | ||||
|---|---|---|---|---|
| eradicated | untreated | untreated | p-value | |
| Federman | 59/191 (30.9%) | 18/83 (21.7%) | 10/74 (13.5%) | p = 0.008 |
| This review | 275/447 (61.5%) | 43/128 (33.6%) | 36/121 (29.7%) | p < 0.001 |
Abbreviations: HP, Helicobacter pylori; CU, chronic urticaria